Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria | Zendy

Guergana Petrova | Zendy; Tanya Strateva | Zendy; Dimitrinka Miteva | Zendy; Snezhina Lazova | Zendy; Penka Perenovska | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria

Author(s) -

Guergana Petrova,

Tanya Strateva,

Dimitrinka Miteva,

Snezhina Lazova,

Penka Perenovska

Publication year - 2016

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.7658

Subject(s) - tobramycin , amikacin , piperacillin , medicine , antimicrobial , cefepime , ceftazidime , cystic fibrosis , ciprofloxacin , pseudomonas aeruginosa , gentamicin , minimum inhibitory concentration , antibiotics , microbiology and biotechnology , imipenem , antibiotic resistance , biology , bacteria , genetics

In aim to achieve better infection control and possible eradication of the pathogens involved in chronic infections of patients with cystic fibrosis (CF) scientists have developed a new way to administer antimicrobials - inhalation. The first and so far the only available inhalable antimicrobial in Bulgaria is inhaled tobramycin (TOBI), introduced in 2009. We aimed to evaluate the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients before and after initiation of TOBI in the regular treatment regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research